Storia in 4 fonti

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the drug has demonstr | After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo5 h fa

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

originale

endpoints.news1 g fa

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD.

Leggi questa versione → originale

benzinga.com1 g fa

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution process.

Leggi questa versione → originale

fiercebiotech.com9 h fa

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted…

Leggi questa versione → originale

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Confronto fonti

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

Timeline cronologica

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Confronto fonti

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

Timeline cronologica

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)

Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win